The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
 
Vatche Tchekmedyian
Stock and Other Ownership Interests - Biomarin; Global Blood Therapeutics; Halozyme; Infinity Pharmaceuticals; Inovio Pharmaceuticals; Portola Pharmaceuticals; Trillium Therapeutics
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Loxo; Novartis
Research Funding - Eisai; Plexxikon; Roche/Genentech
 
Lara Dunn
Research Funding - Pfizer; Regeneron
 
Crystal Tran
No Relationships to Disclose
 
Nora Katabi
No Relationships to Disclose
 
Ai Ni
No Relationships to Disclose
 
Sofia Haque
No Relationships to Disclose
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AstraZeneca; Bayer; Boehringer Ingelheim; Exelixis; Genentech/Roche; Incyte; Lilly; MedImmune; Merck; Novartis
 
Alan Loh Ho
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Genzyme; Kura Oncology; Merck; Novartis; Novartis; oncology consortium; Regeneron; Sun Pharma; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Omniprex America
Research Funding - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly
Travel, Accommodations, Expenses - Ignyta; Janssen Oncology; Kura Oncology; Merck